T he question, "Why can't pharmaceutical companies market products with trade names that do not sound or look like other drug names?" is often asked. Unfortunately, as with most other problems that won't go away, there is no simple answer. The last thing a company wants is trouble with a name that would delay marketing of a drug, cause harm, or force a name change after a product has been marketed. Companies want to create name recognition as early as possible. This is important for safety as well as sales. If a nurse or pharmacist is unfamiliar with a drug name, they may not recognize it when they see or hear it and may mistake it for a name they know (confirmation bias). Companies want prescribers to be familiar with trademarks as early as possible, so that when a drug reaches the market, health care professionals will already be aware of the name.
Obviously, before a drug is ready to be launched, the company must have inventory-not only of the product itself, but of the product label, package insert, and advertising material. In the case of oral solid dosage forms, some companies place the trademark on the tablet or capsule. In the case of tablets, being ready for launch means ordering and testing tablet punches.
Imagine that a product is projected to have sales of $500 million per year, and the launch date is delayed for months because of problems with a proposed trademark. This can affect Wall Street's evaluation of the company's prospects to meet projected earnings. Stockholders can become upset and heads may roll (fairly or unfairly).
Changing a product's name after launch can cost a company as much as 5 to 10 million dollars.
An article in this issue, "Drugs That Look and Sound Alike" (page 1160), lists trademark and generic names that can look or sound alike. The article also describes what government agencies, nongovernment agencies, the pharmaceutical industry, health care professionals, and consumers can do to lessen the likelihood of medication mixups.
As more and more products are being marketed and as companies become internationalized, it is becoming more difficult to choose names without error potential. However, with effort and cooperation among all involved parties, error potential can be reduced.
Errors will never be totally eliminated. Some prescribers will continue to communicate poorly and thus unwittingly set traps for fellow health care professionals, who will mishear or misread drug names. This problem can be reduced, however, by using computerized order entry with programs that have built-in error detection abilities. Such systems must be user friendly to be readily accepted.
Until such systems are in widespread use, we must all do our jobs better by developing and testing product names, writing complete and legible orders, keeping current on available drugs, making sure that prescribed drugs match the conditions being treated, discussing drugs with patients, and being informed consumers.
